PATENT CLAIM ANALYSIS

Application Number: 15761676
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-12
Patent Classification: ["424", "450000"]

Abstract:
The present invention provides improved stable liposomal formulations and method of preparation thereof. The liposomal formulations include liposomes containing a phosphatidylcholine lipid, a sterol, a PEG-lipid, and a taxane, wherein the taxane is docetaxel or a derivative thereof. The liposomal formulations have improved stability and extended shelf-life. The present invention also provides pharmaceutical compositions comprising a liposomal formulation for the treatment of cancer.

Claim (Index 14):
The liposomal formulation of  claim 1 , wherein the liposomal formulation comprises:\n i) from about 50 mol % to about 70 mol % of DSPC and from about 25 mol % to about 45 mol % of cholesterol, ii) about 53 mol % of DSPC, about 44 mol % of cholesterol and about 3 mol % of DSPE-PEG-2000, or iii) about 66 mol % of DSPC, about 30 mol % of cholesterol and about 4 mol % of DSPE-PEG-2000.

Metadata:
- Claim Count in Document: 45.0
- Percentile: 90.0
- Lexical Diversity: 1.69048
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15407512', '15253307', '14255637', '15301570', '14208297']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7798590800063254
- 35 USC 102 Novelty (BERT): 0.5274736199149208
- Combined Prediction Score: 0.754620533997185
- Mean Citation Score: 330.527132
- Max Citation Score: 337.90787
- Similarity Product: 213.87089376681388

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test